H EAT-SHOCK PROTEIN 90 (Hsp90), one of the most abundant molecular chaperones in vertebrates, is essential for regulating the folding and activity of a wide variety of important cellular proteins. In addition to the classic chaperone function, Hsp90 and its cochaperones also serve to regulate client protein activity. Proteins known to be clients for Hsp90 include steroid hormone receptors, aryl hydrocarbon receptor, Src-related tyrosine kinases, various serine/ threonine kinases, telomerase, and nitric oxide synthase. A comprehensive Hsp90 client list is maintained by Didier Picard at the University of Geneva and can be accessed at http://www.picard.ch/downloads/ Hsp90interactors.pdf. Much of our current understanding of interactions between Hsp90, cochaperones, and client proteins is modeled on extensive characterizations of steroid receptor complexes. Steroid hormone receptor folding to a functionally mature state requires ordered assembly with multimeric chaperone complexes (reviewed in Refs. 1 and 2). The final stage of receptor maturation, at which the receptor is competent for hormone binding, involves receptor assembly with Hsp90 and the cochaperone p23; additionally, the mature complex contains any one of several cochaperones that compete for binding the Hsp90 C terminus. These latter cochaperones share a tetratricopeptide repeat (TPR) domain that mediates binding to the highly conserved MEEVD sequence that terminates cytoplasmic Hsp90.
H EAT-SHOCK PROTEIN 90 (Hsp90), one of the most abundant molecular chaperones in vertebrates, is essential for regulating the folding and activity of a wide variety of important cellular proteins. In addition to the classic chaperone function, Hsp90 and its cochaperones also serve to regulate client protein activity. Proteins known to be clients for Hsp90 include steroid hormone receptors, aryl hydrocarbon receptor, Src-related tyrosine kinases, various serine/ threonine kinases, telomerase, and nitric oxide synthase. A comprehensive Hsp90 client list is maintained by Didier Picard at the University of Geneva and can be accessed at http://www.picard.ch/downloads/ Hsp90interactors.pdf. Much of our current understanding of interactions between Hsp90, cochaperones, and client proteins is modeled on extensive characterizations of steroid receptor complexes. Steroid hormone receptor folding to a functionally mature state requires ordered assembly with multimeric chaperone complexes (reviewed in Refs. 1 and 2). The final stage of receptor maturation, at which the receptor is competent for hormone binding, involves receptor assembly with Hsp90 and the cochaperone p23; additionally, the mature complex contains any one of several cochaperones that compete for binding the Hsp90 C terminus. These latter cochaperones share a tetratricopeptide repeat (TPR) domain that mediates binding to the highly conserved MEEVD sequence that terminates cytoplasmic Hsp90.
Among the TPR cochaperones observed in steroid receptor complexes are two large members of the FK506-binding protein (FKBP) family of peptidylprolyl isomerases (PPIases), FKBP52 and FKBP51. The FKBPs are characterized by a conserved domain that is the binding site for immunosuppressive drugs and has PPIase activity (3). Our lab has previously shown that FKBP52 has a stimulating effect on receptors for glucocorticoid (GR), androgen (AR), and progesterone (PR) in yeast and mammalian cell models. Potentiation of receptor activity requires both Hsp90 binding ability and an intact PPIase domain (4) (5) (6) , but the mechanism of receptor potentiation is not known. The physiological importance of FKBP52 in steroid receptor com-plexes is supported by the fact that male mice lacking the gene encoding FKBP52 have ambiguous external genitalia, nipples retained into adulthood, and dysgenic prostate and seminal vesicles, features consistent with androgen insensitivity (6, 7) . Female mice lacking FKBP52 are infertile due to uterine defects in implantation that result from progesterone insensitivity (5, 8) . Our lab and others have shown that FKBP51 can inhibit FKBP52-mediated potentiation of receptor activity (4, (9) (10) (11) and that FKBP51 gene expression is inducible by some steroid hormones (9, (12) (13) (14) (15) . In support of an inhibitory role for FKBP51, constitutive overexpression of FKBP51 underlies cortisol resistance in New World primates (16, 17 (20) , and a C-terminal TPR domain that is required for Hsp90 binding. FKBP51 and FKBP52 have similar PPIase activity toward peptide substrates and Hsp90-binding ability (21) . Given their structural and functional similarities, one might expect redundancy in FKBP function, but this is clearly not the case in relation to steroid receptor activity. Presumably, amino acid sequence differences account for the unique ability of FKBP52 to potentiate steroid hormone receptor function.
One structural distinction between the two FKBPs lies in a seven-to nine-amino-acid loop that connects FK1 and FK2 (FK linker). Beginning at amino acid 141, the respective FK linker sequences, with differences underlined, are DLTEE/EDGG (FKBP52) and DLFEDGG (FKBP51). Interestingly, FKBP52 is readily phosphorylated at T143 by casein kinase II (CKII) in vitro, and other evidence suggests that this phosphorylation blocks FKBP52 binding to Hsp90 (22) . Another study presented evidence that the FKBP52 FK linker contributes to cytoskeletal interactions of the GR heterocomplex (23) . Because the FK linker of FKBP51 differs in sequence and lacks a phosphorylation site, we elected to analyze this region of FKBP52 in greater detail to determine whether the FK linker and/or FK linker phosphorylation are functionally important for FKBP52-mediated potentiation of steroid receptor activity.
RESULTS

Comparative Analysis of FK Linker Sequences
Although highly similar, FKBP51 and FKBP52 have divergent roles with respect to the regulation of steroid receptor activity. In a search for functionally relevant sequence differences, we focused on distinct sequences (boxed in Fig. 1 ) within the linker between FK domains. The FK linker contains the sequence 143-TEEED in FKBP52 and 143-FED in FKBP51. As seen in an x-ray crystallographic structure of the FKBP52 FK domains (Fig. 2) , the FK linker is in an accessible position that could accommodate interaction with proteins or other cellular factors. To test whether the FK linker of FKBP52 influences Hsp90 interactions or steroid receptor activity, we generated site-directed mutants targeting this region (Fig. 3) . In one mutant, the distinctive TEE sequence of the FKBP52 FK linker was substituted by the corresponding F found in FKBP51 (52-LS); in another, E144 and E145 were substituted with arginines (52-RR) to test the importance of negative charges within the linker. When compared with wild-type FKBP52 (52WT), these mutants are unaffected in their ability to associate with general or p23-containing Hsp90 complexes in vitro (Fig. 3A) . To assess FKBP52 mutant function in cells, we employed an established yeast model for FKBP52 activity (4) in which steroid receptors drive expression of a ␤-galactosidase reporter gene in a hormone-dependent and FKBP52-enhanced manner. We have previously shown that FKBP52 potentiates by severalfold transactivation of reporter activity by GR (4), PR (5), or AR (6) . Additionally, the AR-P723S mutant, first identified in an individual with complete androgen insensitivity syndrome (24) , was shown to require FKBP52 for functional rescue (6) and thus provides a hypersensitive marker for FKBP52 activity. As seen in Fig. 3B , 52-LS functions equally well as 52WT to potentiate the activities of GR and AR and to rescue the function of AR-P723S; FKBP52-RR also was fully functional in receptor potentiation assays (results not shown). We further tested whether an FKBP51 mutant containing the TEEED linker sequence would gain any potentiation activity, but none was observed. Therefore, we conclude that differences in the FK linker do not contribute to the functional differences in FKBP52 and FKBP51. On the other hand, as we show below, the FK linker of FKBP52 is a potentially important determinant for regulating the ability of FKBP52 to potentiate receptor function.
FKBP52 Phosphorylation
FKBP52 was previously shown to be phosphorylated by CKII in COS7 cells, and the major phosphorylation site was identified as T143 (22) . To assess the phosphorylation status of FKBP52, we prepared a rabbit polyclonal antibody against a synthetic peptide [FKGEDLT(PO 4 )EEEDGGI] that corresponds to the FK linker containing phosphorylated threonine. After removal of antibodies recognizing nonphosphorylated peptide and subsequent purification on a phosphopeptide affinity column, the resulting monospecific antibody (p52-62) was shown to detect phosphopeptide in a highly specific manner (Fig. 4A) ; additionally, p52-62 cross-reacts on Western blots exclusively with purified recombinant FKBP52 that has been treated with CKII in vitro (Fig. 4B) . To confirm that p52-62 is specific for phospho-T143 and not other phosphorylated sites, we compared immunoreactivity of CKIItreated 52WT or a T143A point mutation that selectively ablates the T143 phosphorylation site; in contrast to 52WT, no p52-62 cross-reactivity was detected with CKII-treated 52-T143A (data not shown). We next used p52-62 to probe the phosphorylation status of FKBP52 in cells (Fig. 4C) ; phospho-FKBP52 was readily detected in extracts from HeLa cells overexpressing exogenous CKII and FKBP52, but basal phosphorylation of endogenous FKBP52 was not detected.
Functional Consequences of T143 Phosphorylation
To assess the possible functional consequence of T143 phosphorylation, we compared 52WT with 52-T143A and a phosphomimetic point mutant (52-T143E). Radiolabeled 52WT and mutants were recovered equally well by immunoprecipitation of total Hsp90 complexes or the subset of Hsp90 complexes containing the p23 cochaperone, and recovery was equivalent in PR complexes assembled in vitro (Fig. 5) . The ability of 52-T143E to still bind Hsp90 and assemble with receptor complexes is somewhat surprising based on a previous report that T143 phosphorylation inhibits Hsp90 binding (22) . We attempted to assess more directly by in vitro assays with purified proteins whether phosphorylation of T143, in contrast to phosphomimetic mutation at this site, blocks Hsp90 binding. However, this approach was not possible because we found that in vitro phosphorylation of purified recombinant FKBP52 by CKII resulted in nonspecific sticking of phospho-FKBP52 to various affinity resins.
As a consequence of this sticky nature, the phospho-FKBP52 (as opposed to non-CKII-treated protein) was quantitatively recovered in high molecular weight aggregates after cross-linking and electrophoretic separation of proteins (results not shown). Because the 52-T143A mutant displayed similar aggregation after CKII treatment in vitro, the apparent misfolding of FKBP52 can be attributed to modification at sites other than T143.
In contrast to the similar properties of wild-type and mutant FKBP52 forms in immunoprecipitation trials, a distinct difference was observed in assays that measure FKBP52-mediated potentiation of steroid receptor function in a yeast model. The phosphomimetic 52-T143E failed to potentiate GR or AR activity (Fig. 6 ). 52-T143A exhibits somewhat reduced activity, al-
Fig. 3. Function of FK Linker Mutants
A, 35 S-Labeled FKBP52 (WT, 52-LS, or 52-RR) were synthesized in vitro and added to normal rabbit reticulocyte lysate. Protein complexes were coimmunoprecipitated from the lysate mixtures using a nonspecific monoclonal antibody (control), a monoclonal antibody targeting total Hsp90 complexes, or a monoclonal antibody specific for p23 that precipitates the subset of Hsp90 complexes containing p23. Images shown are of Coomassie-stained SDS gel separations (upper panels), an autoradiograph of the same gels (middle panel, bound), and an autoradiograph of a gel containing aliquots of the FKBP52 synthesis products (lower panel, input). The migration positions for Hsp90 and the precipitating antibody heavy chains (HC) are indicated. B, Yeast carrying a steroid hormone-responsive ␤-galactosidase reporter plasmid and a GR, AR, or AR-P723S expression vector were cotransformed with empty vector (Vect.) or the indicated FKBP expression vector and assayed for hormone-dependent expression of ␤-galactosidase. Reporter expression was induced with 200 nM deoxycorticosterone (GR), 0.5 nM dihydrotestosterone (AR), or 10 nM dihydrotestosterone (AR-P723S). Data are plotted as fold induction over the level of ␤-galactosidase activity seen in cells carrying empty vector.
Fig. 4. Phosphospecific Antibody and CKII-Dependent Phosphorylation of FKBP52
A, Monospecific rabbit polyclonal antibody was prepared against a synthetic peptide corresponding to the FK linker of FKBP52 and containing phosphothreonine at the position equivalent to T143. Antibody titer was measured in an ELISA against phosphopeptide (pT143) or control peptide lacking phosphorylation (T143). B, Purified recombinant FKBP52 (amounts shown) was treated in vitro with or without CKII, as indicated. Protein was separated on SDS gels and immunoblotted with phosphospecific antibody (p52-62) or monoclonal antibody recognizing total FKBP52 (Hi52D). C, HeLa cells were transiently transfected with an empty plasmid vector (Vect.), plasmid expressing FKBP52 (52), or CKII␣ (CKII) or a mixture of plasmids expressing both FKBP52 and CKII (52ϩCKII). Forty-eight hours after transfection, cell extracts were prepared and Western immunostained for phospho-FKBP52 (p52-62) or total FKBP52 (Hi52D). Purified recombinant FKBP52 that was treated or not with CKII in vitro (right panels) was Western immunostained in parallel with cell extracts (left panels).
though not with all receptors or in a consistent manner between repeat experiments in the yeast model; 52-T143A has full activity in the alternative cellular assay described next.
To corroborate results obtained with the yeast model, we assayed FKBP52 function in a more relevant mammalian cell model. Immortalized mouse embryonic fibroblast (MEF) cell lines were generated from wild-type or fkbp52 null (52KO) mouse littermates (6) . These cells were first used to measure the ability of FKBP52 mutants to rescue AR-P723S transcriptional activity (Fig. 7A) . In wild-type MEF, endogenous FKBP52 appears to be limiting because overexpression of 52WT or 52-T143A elevates receptor function; 52-T143E fails to elevate receptor function. In 52KO MEF, which lack endogenous FKBP52, AR-P723S function is minimal unless rescued by expression of exogenous FKBP52, either 52WT or 52-T143A; in contrast, the phosphomimetic 52-T143E fails to rescue AR-P723S function.
FKBP52 has been shown to be critical for normal PR function in mice (5). The PR-B isoform was introduced into the different MEF genetic backgrounds in combination with a hormone-dependent luciferase reporter and empty vector or plasmid expressing an FKBP52 variant (Fig. 7B) . Endogenous FKBP52 is sufficient in wild-type MEF to fully support PR-B function because progesterone-dependent reporter activity was unchanged by overexpression of exogenous FKBP52. In 52KO MEF, PR-B retains activity albeit at a reduced level compared with wild-type MEF activity. Expression of exogenous FKBP52, either 52WT or 52-T143A, restores PR-B activity; however, 52-T143E failed to elevate PR-B activity. The inactivity of 52-T143E cannot be attributed to a lack of protein because Western immunostains confirmed equivalent levels of 52WT, 52-T143A, and 52-T143E in all MEF extracts (data not shown).
Although the data presented above (Figs. 6 and 7, A and B) suggest that T143 phosphorylation abrogates FKBP52 potentiation of receptor function, it is possible that the phosphomimetic T143E mutation does not fully mimic actual T143 phosphorylation. To assess phosphorylation more directly, we attempted overexpressing exogenous CKII in MEF cells coexpressing receptor and reporter. However, using p52-62 to detect T143 phosphorylation of endogenous FKBP52 in cell extracts, no phospho-FKBP52 was detected in the MEF background (results not shown). Consistent with an apparent lack of FKBP52 phosphorylation, CKII overexpression had no effect on hormone-induced reporter activity. In an alternative approach, CKII was overexpressed in HeLa cells that contain an AR-luciferase reporter system. As shown in Fig. 4C , phospho-FKBP52 can be detected in this cellular background. In cells overexpressing CKII, we consistently observed an approximately 30% reduction in androgen-induced luciferase activity (Fig. 7C) , which is consistent with a phosphorylation-dependent reduction in FKBP52-mediated potentiation of AR activity.
Phosphorylation-Induced Remodeling of the FK1 Catalytic Domain
Of the various mutations introduced in the FK linker, the only change that consistently and substantially impairs FKBP52 function is the phosphomimetic T143E substitution. 52-T143E retains binding to Hsp90 and assembles normally with PR in vitro (Fig. 5 ) yet fails to enhance receptor function in cells (Figs. 6  and 7 ). This mutation is unlikely to have a major impact on FKBP52 folding because protein-protein interactions are maintained, and mutant protein accumulates in cells at levels equivalent to 52WT. Nonetheless, mutation could impose a relevant conformational change, so we employed circular dichroism (CD) measurements and molecular dynamics simulations to compare the conformational states of purified recombinant FKBP52 variants. The far-UV CD spectra suggest no dramatic structural differences (Fig. 8A) , although minor structural changes are apparent. The near-UV CD spectra further indicate that the major tertiary structure remains unchanged by the introduced mutations. However, there are clear differences in certain parts of the spectrum indicating local changes in structure (Fig. 8B) .
Molecular dynamics simulations suggest that the FK linker adopts a more open conformation in the 52-T143E variant (Fig. 9) . Additionally, the simulated FK domains are slightly distorted by the T143E mutation, with a greater change predicted for FK1. For example, G139 (highlighted in red) loses contact with the ␤-sheet in the FK1 domain. ␤-Sheets of the FK1 domain rearrange, and the short ␣-helix also changes orientation. The molecular dynamics simulations, in agreement with CD measurements, suggest that phosphorylation of T143 is unlikely to alter secondary or tertiary structure in a substantial way.
Given the alterations predicted for FK1, it is conceivable that the PPIase activity of phosphomimetic FKBP52 is likewise modulated in terms of substrate specificity or turnover rate. Thus, we compared the PPIase activity of 52WT, 52-T143A, and 52-T143E toward two different proline-containing peptides: SucAla-Ile-Pro-Phe-pNA and Suc-Ala-Leu-Pro-Phe-pNA (Table 1) . Taking the error into account, none of the PPIase activities measured for 52WT, 52-T143A, or 52-T143E were significantly different.
DISCUSSION
FKBP52 is an Hsp90-associated cochaperone that potentiates steroid hormone receptor-mediated transactivation in both yeast and mammalian cell culture systems (4, 6) , and the physiological significance of FKBP52 activity is confirmed by mouse gene knockout models (5) (6) (7) (8) 25) . Although FKBP51 has a high degree of similarity to FKBP52, FKBP51 fails to potentiate receptor activity and is known to inhibit FKBP52-mediated potentiation (4, 9-11), so we postulated that particular sequence differences between FKBP52 and FKBP51 underlie functional differences. The FK linker located between the FK1 and FK2 domains contains a distinctive sequence, and previous reports (22, 23) localized functional properties to the FK linker of FKBP52 that we thought could be relevant to receptor potentiation. Although our findings demonstrate that the amino acid sequence within the FK linker does not distinguish the receptor potentiation capabilities of FKBP52 and FKBP51 (Fig. 3) , we provide evidence that differential phosphorylation of T143, which is unique to the FK linker of FKBP52, has a major effect on potentiation activity. Subsequent to generation and validation of a phosphospecific antibody (Fig. 4, A and  B) , we confirmed an earlier report (22) that T143 is phosphorylated by CKII in vitro and in cells (Fig. 4C) . Additionally, we generated T143 phosphodeficient and phosphomimetic mutants of FKBP52 and found that the phosphomimetic mutant is unable to potentiate steroid receptor function in cells (Figs. 6 and 7) . These findings raise the possibility that differential phosphorylation of FKBP52 could serve as a novel mechanism for regulating cellular responsiveness to steroid hormones.
Whereas our data suggest that FK linker phosphorylation abrogates FKBP52-mediated potentiation of steroid receptor activity, the mechanism by which FKBP52 activity is blocked is unclear. The steadystate level of FKBP52 in cells is unaffected by phosphomimetic mutation (Figs. 6 and 7) , and there appears to be no major change in FKBP52 secondary or tertiary structure (Figs. 8 and 9 ). Furthermore, 52-T143E and 52WT assemble equally well into Hsp90 and steroid receptor complexes (Fig. 5) . The PPIase activity of the phosphomimetic mutant 52-T143E was not significantly different from either 52WT or 52-T143A (Table 1) . Thus, T143 phosphorylation appears unlikely to cause overt changes in PPIase catalytic activity. Nonetheless, structural analyses of 52-T143E do indicate allosteric rearrangements in FK1 that could Yeast reporter strains for GR (A), AR (B), or mutant AR-P723S (C) were cotransformed with an empty plasmid vector (Vect.) or plasmid expressing FKBP51 (51WT), FKBP52 (52WT), or FKBP52 harboring the indicated point mutation (T143A or T143E). Yeast lysates were prepared and Western immunostained (upper panels) for the appropriate steroid receptor, total FKBP52, FKBP51, or, as a loading control, the yeast ribosomal protein L3. In parallel, yeast strains were induced with hormone and assayed for ␤-galactosidase activity (lower graphs). In all cases, receptor signaling in cells expressing 52WT and 52-T143A was significantly higher (P value Ͻ 0.001) compared with cells lacking FKBP (Vect.), expressing FKBP51, or expressing the FKBP52 phosphomimetic mutant 52-T143E.
possibly account for loss of receptor potentiation. Importantly, we know that FK1 is required for potentiation of steroid receptor response to hormone (4). We have recently observed that FKBP52-mediated potentiation is independent of PPIase activity but is highly sensitive to amino acid sequence changes in a loop of FK1 that overhangs the PPIase/FK506 binding pocket (Riggs, D. L., M. B. Cox, H. L. Tardif, M. Hessling, J. Buchner, and D. F. Smith, submitted for publication); allosteric conformational changes to the FK1 domain induced by phosphorylation of the FK linker could alter FK1 contacts critical for receptor potentiation.
The FKBP52 crystal structure reveals a hydrogenbonding network between the carbonyl oxygen of signaling in cells expressing CKII␣ was significantly reduced (P value Ͻ 0.001) compared with cells lacking exogenous CKII␣ expression. All data in A-C are expressed as fold induction over luciferase activity observed in the absence of hormone.
Fig. 7. Phosphomimetic 52-T143E Fails to Potentiate Steroid Receptor Activity in MEF
A and B, Either wild-type or 52KO MEF were cotransfected with a hormone-responsive luciferase reporter plasmid, a plasmid expressing either AR-P723S or PR-B, and an empty vector (Vect.) or plasmid expressing 52WT, 52-T143A, or 52-T143E. Cells were induced with or without 10 nM dihydrotestosterone (DHT) or 1 nM progesterone (P 4 ), and cell lysates were assayed for luciferase activity. All data bars represent the average of triplicate samples. In all cases, receptor signaling in cells expressing 52WT or 52-T143A was significantly increased (P value Ͻ 0.05) compared with cells lacking exogenous FKBP52 (Vect.) or expressing the phosphomimetic mutant 52-T143E. C, HeLa Cells constitutively expressing a stable copy of the AR gene were cotransfected with a hormone-responsive luciferase reporter plasmid and an empty vector (Vect.) or plasmid expressing CKII␣. Cells were induced or not with 0.5 nM dihydrotestosterone (DHT), and cell lysates were assayed for luciferase activity. All data bars are representative of four replicate samples. Receptor T143 and the backbone amide of E146, between the T143 hydroxyl and D147 amide, and between Y225 and the side-chain carboxyl of D147 (Fig. 10) . Based on the predicted structure of 52-T143E, phosphorylation of T143 would appear to introduce steric hindrance and disruption of the hydrogen bond network and structural reorientations within the FK linker and FK domains. The FK linker of 52-T143E adopts a widened architecture, and G139 loses contact with ␤-sheet structures in the FK1 domain, possibly increasing flexibility between FK1 and FK2 domains. Another anticipated structural change in FK1 is a twist in the short ␣-helix that forms one side of the PPIase active site relative to ␤-sheet structures that complete the active site.
Previous studies suggested that CKII-dependent phosphorylation of FKBP52 abrogates the ability of FKBP52 to bind Hsp90 (22) . In contrast to that report, we find that 52-T143E and 52WT bind Hsp90 equally well (Fig. 3) . It is possible that in vitro phosphorylation of FKBP52 by CKII, which appeared to result in phosphorylation at additional sites within the Hsp90-binding TPR domain (22) , might inhibit Hsp90 binding through phosphorylation at sites other than T143. If this is the case, then extensive phosphorylation could possibly shut down FKBP52 function by different mechanisms. As noted above, technical difficulties have prevented direct assessment of whether phosphorylation at T143 alone blocks Hsp90 binding, but this seems unlikely based on properties of the 52-T143E phosphomimetic mutant and the lack of other evidence that FK domains participate in Hsp90 binding.
Potential Cellular Role for CKII in Regulating FKBP52 and Steroid Receptor Activities
Consistent with predictive phosphorylation site algorithms, we and others (22) have shown that FKBP52 T143 can be phosphorylated both in vitro and in cells by CKII. Although CKII was at one time thought to be largely an unregulated cellular kinase, more recent evidence indicates that CKII activity is regulated (reviewed in Ref. 26) . CKII is a tetrameric enzyme consisting of two CKII␤ regulatory subunits and two CKII␣ or CKII␣Ј catalytic subunits. In the absence of the regulatory subunit, CKII␣ is constitutively active. One study demonstrated that inositol phosphates can significantly increase CKII activity (27) , and another study showed that growing cells under hypoxic conditions not only caused the up-regulation of CKII␤ and relocalization of this subunit to the plasma membrane but also resulted in nuclear translocation of CKII␣ and increased CKII activity (28) . Finally, there is evidence that heat stress increases CKII activity by redistributing the individual subunits within the nucleus (29) . These precedents for the regulation of CKII activity strengthen prospects that FKBP52 might be differentially phosphorylated by CKII in physiological settings.
The physiological significance of FKBP52 phosphorylation and conditions under which FKBP52 is phosphorylated in vivo are unknown. FKBP52 phosphorylation can be detected in HeLa cells (Fig. 4C) and COS-7 cells (22) that overexpress exogenous CKII, although in preliminary studies, we have not detected native FKBP52 phosphorylation using the phosphospecific antibody p52-62. More extensive analyses of the exact physiological conditions that favor FKBP52 T143 phosphorylation are merited given the attractive opportunity for regulating FKBP52 and steroid receptor activity. FKBP52 T143 phosphorylation may require specific stimuli and occur in a cell-and/or tissue-specific manner, which would make identification of physiological phosphorylation events more challenging.
In summary, we have identified differential phosphorylation of FKBP52 in the FK linker region as a potentially novel mechanism for regulating cellular responses to steroid hormones. The necessity for FKBP52 in both male and female reproductive processes of the mouse and the likely involvement of FKBP52 in pathological states sensitive to glucocorticoids, androgens, or progesterone encourages further study of the mechanisms by which FKBP52 alters steroid receptor function and mechanisms that regulate FKBP52 function.
MATERIALS AND METHODS
Antibody Production
A phosphopeptide corresponding to the human FKBP52 sequence 137 FKGEDLT(PO 4 )EEEDGGI (150) was synthesized by the Mayo Clinic Peptide Synthesis Core Facility (Rochester, MN). A cysteine residue followed by a linker of two glycines was added to the N terminus to facilitate crosslinking. The peptide was cross-linked to keyhole limpet hemocyanin using the maleimide activated immunogen conjugation kit (Pierce, Rockford, IL), and was then used to Structures of the FK domains from 52WT and 52-T143E were derived by molecular dynamic modeling and overlaid to visualize differences. G139, which in 52-T143E loses contacts to a ␤-sheet in FK1, is highlighted in red.
immunize rabbits (Cocalico Biologicals, Inc., Reamstown, PA). The antibody was purified using a two-step protocol on columns containing Ultralink iodoacetyl gel (Pierce) crosslinked to either the phosphopeptide or the control peptide.
The serum was applied to the control peptide column by gravity flow, and the flow-through was then applied to the phosphopeptide column. After extensive washing, antibody was eluted with 100 mM glycine (pH 2.5) and neutralized by the addition of 0.1 vol 1 M Tris (pH 7.5). Purified antibody was assayed for specificity to the phosphopeptide by an ELISA. In short, 96-well Immulon 4 HBX plates (Lab Systems, Franklin, MA) were coated overnight at 4 C in coating buffer consisting of carbonate/bicarbonate (pH 9.5) (Sigma Chemical Co., St. Louis, MO) plus either phosphopeptide or an identical peptide lacking phosphorylation (5 g peptide per well). Coated wells were blocked in 2% BSA prepared in PBS and incubated with serum serially diluted in blocking buffer. Wells were washed three times in PBS supple- mented with 0.05% Tween 20 and incubated with a horseradish peroxidase-conjugated secondary antirabbit IgG antibody (Pierce) diluted 1:10,000 in blocking buffer. After extensive washing, the wells were developed with 1-Step Ultra TMB-ELISA substrate (Pierce), and absorbance was measured at 450 nm.
Mutant cDNA Construction and Plasmids
An in vitro expression vector (pSPUTK; Stratagene, La Jolla, CA) containing the cDNA for human FKBP52 served as template for site-directed mutagenesis (QuikChange kit; Stratagene) to create all mutations in this study. For the loop swap mutation (52-LS) the TEEED sequence within the FK linker was replaced with FED, thereby making the linker identical to that of FKBP51. For another mutant (52-RR) glutamic acids 144 and 145 were replaced with arginines. The ability of the FKBP52 mutants to bind Hsp90 and to assemble in vitro with PR complexes were assessed by coimmunoprecipitation as described previously (30, 31) .
Mammalian Cell Lines and Assays
MEFs were isolated from d-13 wild-type and homozygous 52KO embryos and immortalized as previously described (5). MEF or HeLa cells were cultured at 5% CO 2 in MEM supplemented with 10% fetal bovine serum and essential amino acids. All plasmid transfections were performed in six-well plates at approximately 80% confluence for 3 h using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions at a DNA (g) to Lipofectamine (l) ratio of 1:3 in MEM lacking fetal bovine serum. For Western immunoblot analyses, the cells were lysed 48 h after transfection as described below. For the receptor activity assays, MEF lines were transfected with the following plasmids (1 g each plasmid per well): a hormone-responsive firefly luciferase reporter, a mammalian expression vector (pCI-neo; Promega, Madison, WI) constitutively expressing steroid hormone receptor, and pCI-neo constitutively expressing an FKBP variant. To control for transfection efficiency, each well was also transfected with 50 ng of a constitutive ␤-galactosidase expression plasmid. Twenty-four hours after transfection, cells were treated with hormone in ethanol carrier (concentration of ethanol in media never exceeded 0.01%). Approximately 16 h after hormone addition, cells were lysed by addition of M-PER (Pierce; 200 l/well) and incubation at room temperature for 15 min. Luciferase activity was determined by addition of 100 l luciferase assay reagent (Promega) to 10 l cell lysate in an opaque 96-well plate; light emission was measured immediately in a luminescence plate reader (Lumicount, model BL70000; Packard Instrument Co., Meriden, CT). ␤-Galactosidase activity was measured by addition of 100 l assay reagent (Gal-Screen; Tropix, Bedford, MA) to 6 l lysate in an opaque 96-well plate. After 2 h at room temperature, plates were assayed in a luminescence plate reader. After normalizing for transfection efficiency (relative light units/␤-galactosidase activity), data were plotted as fold induction of luciferase activity over background activity observed in the absence of hormone. Statistical significance was determined by one-way ANOVA followed by pair-wise comparisons using Bonferroni's multiple comparisons test; P values Յ 0.05 determine significant differences.
Yeast Strains and Assays
␤-Galactosidase reporter assays used as a quantitative indicator of steroid hormone receptor activity were described previously (4) . The designer deletion strain BY4741 (MATa his3⌬1 leu2⌬0 ura3⌬0 met15⌬0) with an additional TRP1 gene deletion was the parental strain for GR assays; W303␣ (32) were used to detect FKBP52 and FKBP51, respectively. Specific antibodies to detect AR (PG-21) and GR (BuGR2) were obtained commercially (Affinity Bioreagents, Golden, CO). As protein loading controls, yeast extracts were blotted with antibody recognizing the L3 ribosomal subunit (33) , and mammalian samples were blotted with antibody recognizing glyceraldehyde-3-phosphate dehydrogenase (6C5; Biodesign International, Saco, MN). The secondary antibody was an alkaline phosphatase-conjugated goat antimouse antibody (Pierce), and bands were visualized with Immun-Star AP substrate (Bio-Rad) and exposed to x-ray film.
Recombinant Protein Expression and Purification
His-tagged FKBP52 variants were expressed in Escherichia coli from pET28a ϩ vectors (Statagene). The protein variants were affinity purified from bacterial extracts on a Ni-NTA High Trap column (GE Healthcare, Munich, Germany). After loading and extensive washing with buffer A [50 mM sodium phosphate (pH 7.5), 200 mM NaCl], bound protein was eluted with buffer A plus 300 mM imidazole and dialyzed against 40 mM HEPES (pH 7.5) plus 50 mM NaCl. The eluate was loaded on a ResourceQ column (GE Healthcare) and eluted with a linear gradient from 50 mM to 1 M NaCl. The FKBP eluted at 300 mM NaCl and was judged by SDS-PAGE to be at least 99% pure.
CD Spectroscopy
Purified recombinant proteins were dialyzed against 5 mM sodium phosphate (pH 7.5). Spectra were recorded on a Jasco 715 spectropolarimeter (Jasco, Gross-Umstadt Germany) with a protein concentration of 5 M for all FKBP52 variants at a temperature of 20 C. For the far-UV CD spectra, samples were loaded in a cuvette with a path length of 1 mm, and spectra were recorded from 260-195 nm. Near-UV CD spectra were recorded from 320-250 nm in a 5-mm pathlength cuvette.
Protease-Coupled PPIase Assay
FKBP PPIase activities were measured as described previously (21) . The synthetic peptide substrates were N-succinylAla-Ile-Pro-Phe-p-nitroanilide and N-succinyl-Ala-Leu-ProPhe-p-nitroanilide. Assay mixtures contained purified recombinant FKBP (10-150 nM final concentration), substrate peptide (50 M), and chymotrypsin (1 mg/ml) in 40 mM HEPES (pH 7.5) at 10 C. Because chymotrypsin cleaves only the peptide amide bond preceding the proline moiety in its trans conformation, cis-trans proline isomerization becomes rate limiting for cis peptide cleavage. The reaction was followed by generation of the free chromophore p-nitroanilide, which absorbs at 390 nm. Kinetic traces were fitted to a single exponential equation with floating end point. The experimentally observed rate (k obs ) values were plotted against FKBP52 concentration and fitted by a linear regression to determine the specificity constants.
Molecular Modeling
The structure of the FK1 and FK2 domains of FKBP52 (Protein Databank accession no. 1Q1C) was analyzed in a yamba2 force field with the program Yasara (34) . The simulation cell was centered on the protein structure, and the protein distance from cell boundaries was at least 5 Å. With the pH set to 7.0 and a temperature of 298 K, the wild-type protein structure was analyzed in the molecular dynamic simulation force field for 7 nsec. No structural differences were noted between the simulated and crystal structures. To gauge the potential effects of phosphorylation, threonine at position 143 was converted to glutamic acid, and dynamic simulations were carried out under the same experimental conditions for 5 nsec.
